Originally published in Synapse on March 15, 2007.

NMD Pharma will also present an update on the ongoing SYNAPSE-MG Phase 2b clinical trial of ignaseclant in generalized myasthenia gravis Aarhus, Denmark, 10 March 2026 – NMD Pharma A/S, a ...

Artificial intelligence is everywhere, from chatbots and search engines to video games and face-swap apps. Young people are leading users of the tools, but many don’t know the limitations or how to ...

A major problem in the treatment of addiction is relapse, which is often caused by the powerful and long-lasting memories of the drug experience. Drugs of abuse can hijack or impair specific synaptic ...